Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

football

- PMLiVE

UCB files Vimpat for expanded epilepsy use

Submits monotherapy application to FDA


- PMLiVE

UCB wins extra Cimzia approval in US

FDA backs drug for use in patients with active psoriatic arthritis 

- PMLiVE

Baxter’s Nick Roger joins Bedrock

Takes up role as strategic solutions director at med comms agency

- PMLiVE

Interlace realigns business to focus on communications

Sells off regulatory and pharmacovigilance interests

- PMLiVE

VIDEO interview: Neil Weir, UCB

Senior vice president of global research at UCB discusses the importance of patient-centricity and the value of collaboration

- PMLiVE

UCB’s Steve Arnold joins ABPI board

Will work to support life sciences in the UK

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

EISAI

Eisai’s epilepsy drug Zonegran wins Swiss approval

Swissmedic licences new monotherapy indication for the treatment

- PMLiVE

Saatchi & Saatchi create Spanish restless legs syndrome campaign

Online public awareness push is in collaboration with UCB

- PMLiVE

Spanish pharma recovery won’t begin until after 2014

Country's pharmaceutical market is yet to hit rock bottom

- PMLiVE

Mike Birtwistle and Sarah Winstone to leave MHP Health Mandate

Rupert Gowrley and Rachel Rowson will take over as interim heads

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links